Wednesday, December 19, 2012

Merry Christmas

Dear Friends
Thank you all so very much for all the donations so that it was possible thru Pennies in Action's effort to donate directly to the research for this year alone
$ 280 000 !!!!!! 
I am blown away by your  generosity.
Have a merry Christmas and happy holidays. I know I will knowing that we made it possible for 10 more women to get this vaccine and have amazing results, and get  tools for the lab to further the research...
God bless you all

Sunday, December 9, 2012

A great Christmas idea......

 A great idea for Christmas giving with a great purpose !!!!!!

Tuesday, December 4, 2012

27 days left in 2012

27 days left to make a tax deductible donation to

Monday, December 3, 2012

28 days left in 2012

28 days left to act

29 days in 2012

29 days left to act

30 days left in 2012

you have 30 days to act:

31 days left in 2012

Look us over and see if you want to help with a donation...

32 days left in 2012

If you have tax deductions left for 2012 consider helping this life saving research and vaccine for real patients.

33 days till 2013

These are posters Donna Young (a Pennies in Action crusader )is developing to get the cause out and hopefully people think of us when they still have tax deductable donations to make before years end....

Friday, October 26, 2012

Great idea for Halloween and helping a great cause at the same time.....

Sunday, October 21, 2012

Pennies in Action videos hold the solution to cancer

Our videos for PIA :

The search for the cure

 A cure within

discovering the cure within               -Pennies in Action -kids  2012

check them out and share with your friends. This is the solution to cancer !!!!!!!!!!!!!!!!!!!!!!

Wednesday, October 17, 2012
this is a youtube showing you paddle tennis.

really cool Join us for a day of great fun while you help out an amazing cause...

Tuesday, October 16, 2012

Lou, Babs & Moogs is supporting  Pennies in Action and their research for a
Vaccine against Breast Cancer!

During the month of October, LBM Gifts will donate a percentage of all sales made
on their website .  Take a look and find so many unique gift ideas and great finds!  Gift wrap is FREE and orders over &75 get FREE shipping too!

Keep up with more exciting news on Pennies in Action and supporting Breast Cancer Research for a cure at their blogpost “Who Gives  A Gift.” You can also participate in the Lou Babs & Moogs Facebook Fan Page- Who’s Your Hero Photo month and weekly Fan giveaways. 

Friday, September 7, 2012

upcoming events

Purple the Globe

On becoming a Champion
                                                 Practice and hours of repetition...

As I was taught by my coach “doing things you love to do and are good at is not hard work. But doing what you do not like and what you are NOT good at is where the real work begins “.Without that there will be no progress and no mastery ...

It started quite simply in doing school figures on the ice (which we had to do on either leg and in either direction...) Every body has a good and a bad side ( we called it the chocolate and the lemon leg ) So I had to do 2 :1 or preferably 3 :1 or 4:1.
It takes a lot of discipline to do 4 times more of what you cannot do versus what you already can. It is human nature, but overcoming that sets the champion apart from the rest.

It is very difficult today to keep students onto one thing long enough so they truly solve and master it.

My coach had a great way . When I had a lesson he took on ONE thing each day and he said :”when you solve it you can go home. If you get done in an hour or 8 hours, but you cannot leave until it is solved....”
Solving meant that it was the only way I would do it ,it had became part of me.

I tried that philosophy in my own teaching but only few students had the patients and dedication to do this. But I can report ,that the ones that did ended up on the top of the podium. They also understood that the only practice that counted was great, concentrated practice or it accomplished the opposite by ingraining bad habits.this is true in any walk of life not just sports.

It takes about 21 days of relentless practice to undue a bad habit and 6 months for it to manifest itself as part of the way you do things.

Under pressure you usually revert back to 6 months ago , so the repetition of relentless practice is essential in a life of a champion.
In todays world were we get rewarded just for showing up it is more and more difficult to get mastery. It used to be that you only got credit for achievement . As the they say “We do it the old fashion way we earn it “...

“The older I get the more I watch  what people DO and listen less to what they SAY.  Unless your talk is followed by action it is useless...

I always loved the saying “ God helps the one who helps himself.” I am so scared that we feel we have all these entitlements and we are owed everything. For me that would be stepping out of my comfort range to become comfortable to have others take care of me.

As they say : “ Give a man a fish he eats for a day. Teach him how to fish he eats for a life time.”
Getting back to be engaged in life and participate and reach for goals is where the real excitement of life is. I always said reach for the stars and you will at least reach the moon. 

Your talent is God’s gift to you what you do with it is your gift back to God.!!!

Sunday, August 19, 2012

Not all vaccines are created equal....!!!!

make sure you watch this video !!!!!

Dear Friends,
I have been asked by Uschi Keszler, founder of Pennies in Action, to field some often-asked questions regarding the exciting breast cancer vaccine initiative that she and her organization are supporting. As an experienced Immunologist, and one who has had some involvement in the development of this approach, I feel that I am in an excellent position to offer my personal thoughts and opinions on why this matter should be worthy of your attention and support.
What is this all about? Dr. Brian Czerniecki and his team of investigators have developed a vaccine strategy for secondary prevention of breast cancer. Secondary prevention is the capacity to prevent the recurrence of cancer once the primary tumor has been identified and surgically eliminated. This vaccine strategy temporarily removes some of the breast cancer patient’s own white blood cells prior to surgery. During a 2-day period outside the body the cells are exposed to breast cancer proteins as well as biochemical signals that mimic infection. The cells are then re-administered back to the patient each week for 4-6 weeks prior to the scheduled surgery. The re-introduced white blood cells then signal the body’s immune system to attack the cancer. Whatever remains of the tumor is then surgically removed and the patient is closely followed to monitor for recurrence of disease. When non-vaccinated patients receive the best current standards of care after surgery (including local radiation and chemotherapy), tumors still recur in up to 20-25% of the patients within 5 years. Reducing this number with a vaccine would be the most cost-effective and humane way to prevent all of the morbidity and mortality that occurs as a result of breast cancer recurrence after surgery. This includes local recurrence, metastatic disease, death due to advanced cancer, and all of the financial cost and side-effects of chemo- and radiation therapy.
Why focus on preventing recurrence? Why not develop a vaccine to prevent breast cancer in the first place? It is very difficult to predict who, among those who have never had breast cancer, will develop it within a 3-5 year window. Testing an experimental vaccine for primary prevention would therefore require the immunization of thousands of individuals in order to catch the handful that would otherwise develop it. Such a large trial would be financially prohibitive. On the other hand, individuals who have already developed a high-grade early breast cancer, and had it surgically removed, are at considerable risk for experiencing a recurrence in 3-5 years. By focusing on this high-risk group, it will require fewer vaccinated patients to prove that immunization suppresses recurrence rates. Such a smaller trial is of course more

financially manageable. However, it should be noted that a vaccine that is proven to prevent recurrence would almost certainly also prevent cancer from ever developing in the first place. Therefore the development of a vaccine that prevents recurrence shortens the path to achieving true cancer prevention.  
Does Dr. Czerniecki’s vaccine show any sign of providing secondary protection? In two “phase 1-2” clinical trials conducted at the University of Pennsylvania, over 50 women were vaccinated.  Some of these women have been followed out beyond 88 months (over 7 years). In the subset of women whose breast cancers did not express the estrogen receptor (about half), absolutely no recurrences have been observed. Blood samples taken from women up to 5 years after vaccination demonstrate white blood cells that still respond against breast cancer proteins, indicating a very long-lived immune response, which is necessary to provide extended protection from recurrence.
In what way are these results exciting and different from other breast cancer vaccines I have heard of? First, Dr. Czerniecki has over a seven-year track record of immunizing real people with breast cancer using this vaccine. This is not a pie-in-the-sky idea that has been tried only “in the test tube” or in mouse models. The vaccinated patients have had real, tangible results. Seven of the patients, when sent to surgery after receiving the course of vaccinations, had no detectable cancer left in their breasts. Several of the patients showed such a large degree of tumor shrinkage that the remaining disease could be safely removed using a lumpectomy procedure, rather than having to remove the whole breast. Past attempts by others to produce anti-cancer vaccines show that immunity wanes a few weeks after vaccination. The responses from Dr. Czerniecki’s vaccine have been shown to last for years, potentially offering patients long-term protection from recurrent tumors. Finally, there have been no recurrences in a large subset of our patients. No current therapy, established or experimental, has ever shown this level of prevention. The results of these trials have been published in peer-reviewed journals including Cancer Reserarch (2007), Cancer (2012) and the Journal of Immunotherapy (2012).
Why are these results so good? The body’s immune system is primarily designed to attack microbes (bacteria and viruses). Dr. Czerniecki’s vaccine strategy is unique in that it, by design, “tricks” the immune system into responding against cancer as though it was a dangerous infection. In addition, we are attacking the breast cancer at a very early stage. Remember, the common vaccines against infections that you are familiar with are all preventative. They don’t work once you are already sick. The medical establishment has become very good at detecting breast cancer at earlier and earlier stages. Unfortunately, women with one bout of breast cancer are at high risk for recurrence. The challenge therefore is to develop treatments that will preserve the health of the patient in the long-run without the debilitating and dangerous side-effects of radiation therapy and chemotherapy.
What is the next step? In order to gain approval from the FDA for using this vaccine as a standard therapy, a successful “Phase 3” trial must be completed. Such a trial will be conducted at multiple institutes (so that other groups of physicians can replicate the University of Pennsylvania results), and must involve a larger number of patients (around 200, so that statistics can prove conclusively that we are really preventing recurrence). We can begin such a trial almost as soon as we secure the necessary funds.
If these results are really so good, why hasn’t money already been obtained for the phase 3 trial? The first two phase 1-2 trials were generously supported by prestigious “R01” awards from the National Institutes of Health, which funds the bulk of health-related research conducted at Universities and Biomedical Research Institutes across the United States. Unfortunately, NIH “caps” their awards at $500,000 per year for 4-5 years (2-2.5 million per grant, maximum). Such funds can support early trials involving 30-40 subjects, but we calculate that a multicenter phase-3 trial will cost around 4-6 million dollars. The NIH simply does not have a common funding mechanism that covers something this large. Likewise, private funding organizations such as the American Cancer Society and the Susan G. Komen Foundation place most of their emphasis on awards of similar, smaller scale.
Another avenue would be the formation of a startup company and the attraction of venture capital. Unfortunately, the cancer therapy options that are most profitable are not necessarily the ones that are best and most desirable from the standpoint of the patient. Outside investors may not be able to resist selling out to a generous offer from a large pharmaceutical company. The pharmaceutical company may in turn decide that there is more money to be made selling standard chemotherapy than preventative vaccines and “shelve” their newly-acquired technology. Dr. Czerniecki and his colleagues strongly believe in the entrepreneurial spirit that drives innovation in the United States, but we must acknowledge that we should first strive for a transparent, fully independent demonstration of the vaccine’s effectiveness. Only after the vaccine’s value is common knowledge, and there is considerable demand from the public for this new preventative, should the technology be transferred to business interests. This approach will ensure that the vaccine eventually gets to the people who need it.
Will this vaccine have a large impact on health? Our “proof-of-principal” vaccine is directed at a single protein called HER-2 that is produced by about 30% of all individuals with breast cancer. We are already planning a strategy to expand and improve the vaccine therapy to increase the number of individuals who would benefit from immunization. First, we are pairing vaccination with a short course of the anti-estrogen drug Tamoxifen. Early studies suggest that this combination may improve overall effectiveness for individuals with cancers expressing the estrogen receptor. Second, we are laying the scientific groundwork for including additional cancer-related proteins such as HER-1 and HER-3. A vaccine formulation including HER-1, 2 and 3 could potentially allow protection of up to 90% of breast cancer patients. Perhaps even

more important, these cancer-related proteins are also found on other common cancers including cancer of the lung, pancreas, ovary, colon and prostate. This means that when fully developed, this vaccine technology has the potential to impact some of the most common tumor types.

I hope that I have answered most of your questions, and that you find this cause worthy of your support.

Gary K. Koski, Ph.D.
Associate Professor of Biological Sciences
Kent State University
Kent, Ohio 44242 

Saturday, January 21, 2012

Dr. Czerniecki's state of the research report

State of the Research Report
January 2012

I would like to review the progress we have made over the past year and the tremendous increase in talent now participating on the project, as well as, the number of new members that will be joining this year. Obviously, we have a long way to go to eliminate breast cancer, but progress is beginning to be seen more rapidly this year. I will review our partnerships and the ongoing projects that are aimed at the elimination of breast cancer and other cancers. Below is a summary of activities, followed by a short description of each one.
 Publications:
o Journal of Immunotherapy, January 2012  A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer Koski, Gary K.; Koldovsky, Ursula; Xu, Shuwen; Mick, Rosemarie; Sharma, Anupama; Fitzpatrick, Elizabeth; Weinstein, Susan; Nisenbaum, Harvey; Levine, Bruce L.; Fox, Kevin; Zhang, Paul; Czerniecki, Brian J. Journal of Immunotherapy. 35(1):54-65, January 2012. doi: 10.1097/CJI.0b013e318235f512
o Cancer, Journal of American Cancer Society will be –published in next few months
o Cancer Prevention Book, chapter about Vaccines in Breast Cancer Prevention –published later in 2012
o Two manuscripts with the George Coukos Group
 PLoS One. 2011;6(12):e28732. Epub 2011 Dec 14.Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.Chiang CL, Hagemann AR, Leskowitz R, Mick R, Garrabrant T, Czerniecki BJ, Kandalaft LE, Powell DJ Jr, Coukos G.
 Chiang CL, Maier DA, Kandalaft LE, Brennan AL, Lanitis E, Ye Q, Levine BL, Powell DJ Jr, Coukos G: Optimizing the parameters for clinical scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. J Translat Med 9(1):198, 2011.
o Finishing manuscript about freezing the vaccine
 DCIS Second Trial
 Other new HER Family Targets
 HER-3 Immune Response
 Vaccines for Early Invasive Breast Cancer
 Vaccines for Patients with Large HER-2pos Breast Cancer Following Chemotherapy and Herceptin
 Prevention Programs for BRCA Mutation Carriers
 Prime- Boost Vaccines
 Melanoma Vaccines
 Compassionate Use Vaccines for Metastatic Pancreatic Cancer, Triple Negative, and HER-2pos Breast Cancer
We have published two papers this year from our first DCIS trial, alluding to its tremendous success. One was published in the Journal of Immunotherapy in January 2012, and the second will be coming out in Cancer within the next couple of months. Shayna Showalter, our Breast Fellow, and I had put together a chapter about vaccines for a cancer prevention book to be published shortly. Together with the George Coukos Group, we have published two manuscripts demonstrating that the modifications of our dendritic cell vaccine can be used when pulsed with ovarian cancer cells for personalized vaccines. Elizabeth Fitzpatrick, who is our director of vaccine production, is completing a manuscript showing we can successfully freeze our activated dendritic cell vaccines and they retain their activity. This is very important because it means vaccines can be mass produced from patients anywhere and shipped. All of these are major accomplishments in the past year.
In Layman’s Terms: We have been busy scientifically and continue to receive the support of peer-review with our scientific writings
DCIS Second Trial:
We are continuing this trial with around 26 patients accrued and we have modified the trial for patients that are estrogen receptor positive to receive anti-estrogen therapy with vaccines. Our trial was highlighted on the CBS Evening News (11/16/2011). The patient highlighted was the first with our combination anti-estrogen vaccine component and had no disease left at surgery. Immune response rates in this trial are close to 90%, a remarkable outcome. We are continuing the trial through around 54 patients. With the data we have collected we are anticipating applying to the NIH for renewal to expand the anti-estrogen therapy with the vaccine group into Phase II and for those that are estrogen negative HER-2pos add trastuzumab (Herceptin) with vaccines. We anticipate these maneuvers will continue to help us get to complete
responses (meaning no disease left at surgery) for all these patients, eliminating long courses of anti-estrogen therapy (5 years), and reducing the need for radiation therapy and mastectomy rates. We are confident that the vaccines will help reduce recurrence rates and new breast cancers. Elizabeth Fitzpatrick and Shuwen Xu, MD continue to provide the engine for these studies.
In Layman’s Terms: This trial is still accumulating patients rapidly and is heading toward our goal of 50 patients. We are combining vaccines with a brief course of Tamoxifen or Letrozole (aromatase inhibitors) for patients with estrogen positive HER-2 positive DCIS: An exciting combination to block two pathways and increase the number of complete responses.
Other new HER Family Targets:
Holly Graves, a Penn surgery resident, has been performing pathology staining in the lab in patients with DCIS with HER-3, HER-4, HER-1 and survivin. She has made the observation that survivin expression in DCIS increases with grade, and although not associated with invasion, is a good immunologic target independent of HER-Family expression. She is about to submit a paper with Dr. Paul Zhang, in Pathology, describing the role of survivin in DCIS. It is known that this molecule may play a role in recurrence. Holly is also making critical findings with HER-3 and is showing it is expressed in a large number of DCIS lesions. This is great news as it confirms our suspicion that other HER family members are involved in early breast cancer and invasive breast cancer, and is responsible for resistance to some of the breast cancer recurrences following Herceptin. Holly has shown HER-3 expression remains in some of our HER-2 vaccine patients on residual DCIS and thus is prime for targeting. Holly is looking at the association between HER-3 expression and the development of invasive breast cancer in DCIS and it appears to be highly associated like HER-2! Anti-HER-3 vaccines and antibodies would be primed to prevent breast cancer invasion and not only in HER-2 cancers. Data is accumulating that many patients’ breast cancers are HER-3 positive and would be a target for personalized therapy. Herceptin treated patients often fail in the brain (meaning the treatment fails and the cancer moves into the brain) and HER-3 expression is associated with metastatic brain tumors. Others have found HER-3 expression in melanoma, lung cancer, brain cancer, and colon cancer, suggesting a critical target for attack. HER-1 is expressed on a minority of breast cancers, generally triple negative, but is another target of the family. We are trying to convince our pathologists to assess these molecules in all of our breast cancer patients for profiling and therapy decisions. Holly is also looking at other biomarkers in DCIS and including some of these biomarkers in melanoma.
In Layman’s Terms: We are identifying the role of HER-2’s sister protein in early breast cancer so that we can effectively target these and develop other vaccines to help with resistance and recurrence to anti-estrogen and Herceptin therapy. This is important in preventing recurrence.
HER-3 Immune Response:
Sara Matthews, a Penn surgery resident, joined the lab in July to identify peptides from HER-3, survivin, and HER-1 that can be developed and used for our next generation of vaccines. She has started with HER-3 and made amazing progress. She has analyzed the protein and designed peptides for CD8 T cells. She has already identified two of these peptides to which patients can react! This is the first demonstration of peptides from HER-3 that can be used for targeting HER-3. She is now testing tumor cells to find HER-3 expression so as to use these CD8 T cells to determine whether they can recognize and kill HER-3 expressing cancers. She has done the same with CD4 peptides and will be testing those shortly. She has really settled in well and will test normal donors for HER-3 activation as well. She will continue with HER-1 and survivin. This is exciting because we are going to be able to rapidly add these peptide targets to vaccines for patients with breast cancers and melanoma. Other tumors such as ovarian cancer, colon cancer, pancreatic cancer, and lung cancer are also targets for these HER-3 vaccines.
In Layman’s Terms: We are already beginning to develop the peptides that can be used to target HER-3, attacking a critical path in cancer development in estrogen positive, HER-2 positive and triple negative breast cancer. This work is the prelude to bringing this into the clinic very shortly.
Vaccines for Early Invasive Breast Cancer:
Inspired by one of our vaccine patients, we are committed to use our HER-2 dendritic cell vaccine in combination with Herceptin (3 doses) for patients with early HER-2pos breast cancer. This would be the first trial for these patients without the use of chemotherapy. PURE IMMUNOTHERAPY! Dr Carol Tweed, a medical oncologist, is supporting and developing this protocol. We are applying for funding for this trial. All patients will have T1a T1b HER-2pos (≤1 cm) breast cancer. This may be the beginning of the end for chemotherapy.
Vaccines for Patients with Large HER-2pos Breast Cancer Following Chemotherapy and Herceptin:
We are developing a breast cancer vaccine with HER-2 and HER-3 to give patients after chemotherapy and Herceptin to help prevent recurrence. Dr. Angela DeMichele, in Medical Oncology, is helping to develop clinical trials that can be used for these patients. The HER-3 vaccine we are developing will be critical in this trial. Rachel Yang, a medical student, is looking at the immune responses that develop in these patients from chemotherapy and Herceptin. This study will be open in February and we will be recruiting patients to give us blood to see whether the development of a cellular immune response is associated with preventing recurrence. Anyone in this category we need your blood help us out.
We are hopeful that we will be able to get the Abramson Cancer Center to support a Translational Center of Excellence for Secondary Prevention of Breast Cancer. A lot of breast cancer patients fear the recurrences that can develop even many years after eliminating the primary disease. I suggest you support this cause by letting the Abramson Cancer Center Director Chi Van Dang and Hospital Administration Ralph Mueller know that you support and demand such a novel program.
In Layman’s Terms: A late recurrence is something all breast cancer patients fear. We are developing the tools to predict immune response in patients treated with Herceptin as to who will and will not recur, and use our vaccines for those that are likely to recur to prevent a late recurrence. We want to develop a center for breast cancer patients devoted to determining and reducing their risk of recurrence without having to wait 10 or 15 years until recurrence happens! This would be the first center of its kind in cancer care. I suggest you support this cause by letting the Abramson Cancer Center Director Chi Van Dang and Hospital Administration Ralph Muller know that you support and demand such a novel program.
Prevention Programs for BRCA Mutation Carriers:
Rachel Yang, a medical student, is spending a year with us evaluating the DCIS and Breast Cancer patients with HER-family members that are mutation carriers as a first step to assessing whether our HER family dendritic cell vaccines can be utilized for these patients that often have a 70% lifetime risk of breast cancer. If these patients have HER-1, HER-2 or HER-3 expression on their tumors then it would make sense that this would be the ideal group in which to test a breast cancer prevention vaccine. Dr. Susan Domcheck, the Director of the High Risk Screening Genetic Clinic at Rowan Breast Center, is assisting with this project.
In Layman’s Terms: We are identifying targets in patients that have inherited the breast cancer genes to offer them vaccines for prevention as alternative to bilateral mastectomies. That’s a good thing: who at 20 or 30 should face bilateral mastectomies?
Prime-Boost Vaccines:
Dr. Gary Koski, our colleague at Kent State, is busy at work identifying the peptides that Herceptin and pertuzumab recognize so that we can add these peptides to our current vaccines so that patients can make their own Herceptin and pertuzumab. We will also identify peptides that can be used to generate antibodies against HER-3 and HER-1. This is exciting and will be used with our early breast cancer vaccine trials and our late adjuvant HER-2, HER-3 Vaccines. This data is moving along very nicely. This is our next big addition to these vaccines.
In Layman’s Terms: We can teach patients’ own immune systems to make their own Herceptin and pertuzumab for lifelong surveillance against recurrence.
Melanoma Vaccines:
Jessica Cintolo, a Penn Surgery Resident who started in July, is working in a mouse model and in human melanoma to assess whether vaccines can be developed against the melanoma protein BRAF and HER-3. She has a model of melanoma development in the mouse that is caused by BRAF. Working with our colleagues at Wistar Institute, she is studying anti-BRAF vaccines and combinations of BRAF kinase medications and vaccines in melanoma therapy. Jessica, with Holly Graves, is assessing HER-3 expression in patients receiving BRAF kinase drugs to determine whether HER-3 vaccines combined with BRAF will be useful to eliminate metastatic melanoma. Jessica has the mouse models approved and is purchasing mice for breeding while assessing the HER-3 expression in patients with metastatic melanoma.
In Layman’s Terms: Our vaccine program can be used to combat melanoma that has spread and try to reduce deaths in this deadly disease. We will combine it with the new melanoma targeted therapy to eliminate remaining cells that often become resistant to drug therapy
Compassionate Use Vaccines for Metastatic Pancreatic Cancer, Triple Negative, and HER-2pos Breast Cancer:
We have lost some good friends to pancreatic cancer and metastatic breast cancer and therefore are bringing in some of our new peptides against HER-1, survivin, and Mesothelin
against these metastatic cancers. Unfortunately, we have only CD8 peptides for these antigens thus far, so we will use our HER-2 backbone. However this means all the patients being treated have to be HLA A2 haplotype to be able to derive any benefit. This type of study is impossible to fund because of the nature of the vaccine and the stage of patients, but we are happy that Pennies in Action will supply money so that these patients can receive the vaccine. The trial is with the FDA and the IRB. Currently we anticipate being able to provide vaccines for patients by late February or early March. Each of these treatments cost about $5,000-$10,000 per patient.
In Layman’s Terms: We can offer some hope to those that have metastatic breast cancer (triple negative or HER-2 positive) or those with metastatic pancreatic cancer to try to get their immune response rolling after they have finished chemotherapies. Pennies in Action is supporting this endeavor completely as no scientific funding agency would take on a task like this. We will get Phase I data as a result with new targets.
As can be seen, there is a lot of activity ongoing in the group. We have three others joining the lab this spring and summer. As a result of the Henle Foundation support, we have been able to provide a new two year research fellowship experience. This year, starting later in the spring, Eric Berk will join the lab from the University of Pittsburgh. Eric will complete his PhD in March in dendritic cell biology with Dr. Pawel Kallinski. He will study T cell dendritic cell interactions. Kathryn Lee, a Penn Surgery resident, will join us in July and Megan Fracol, a medical student at Penn, will join us in the summer for eight weeks and study whether our T cells and antibodies from vaccinated patients can prevent in 3D models Breast Cancer Invasion. Megan has learned Penn selected her project above all other students for national competition. We are also pretty sure that Dr. Robert Roses will be returning from MD Anderson to the faculty at Penn and will take a leading role in our Vaccine Projects as well. Robert was a major contributor when he was a resident. We take this opportunity to thank all of our donors and sponsors for both their inspirational and financial support. We hope to bring this annual report to our friends yearly so they can see where we are going. We are indebted to Pennies in Action for the purchase of new incubators, a refrigerator and a microscope for performing our pathology work. Our numbers of young scientists are growing and we are continuing to gain traction. We expect to continue the growth and accomplishments of this group as we report in 2013.
A healthy and Blessed New Year to all our friends,
Brian J Czerniecki, MD, PhD